The harm caused to patients by the cost of cancer care: depleted savings, debt, skipped medication and worse survival. Measured like any other side effect and, increasingly, treated like one.
Coined by Zafar and Abernethy (2013). Components: material hardship (out-of-pocket costs, income loss), psychological distress and coping behaviours (non-adherence, skipping visits). Prevalence 30-50% of US patients; associated with lower quality of life, treatment non-adherence and higher mortality (bankruptcy linked to 79% higher mortality). Measured by the COST-FACIT instrument. Drivers include drug prices, cost-sharing designs, oral-parenteral parity gaps, travel, and employment loss; higher among younger, minority, low-income and rural patients. Financial navigation, assistance programmes, cost conversations and policy (out-of-pocket caps, Medicaid expansion) reduce it.
Most cancers start in the ducts and drain first to the axillary nodes, which is why the armpit is checked and a sentinel node is sampled.
Same organ: Breast cancer (all types), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Male breast cancer, Ductal carcinoma in situ (DCIS), High-risk early HR-positive breast cancer, HR-positive metastatic breast cancer after CDK4/6 inhibitors, HER2-low and HER2-ultralow metastatic breast cancer, Early HER2-positive breast cancer, HER2-positive breast cancer with brain metastases, Early triple-negative breast cancer, Metastatic triple-negative breast cancer, Basal-like 1 triple-negative breast cancer (BL1), Basal-like 2 triple-negative breast cancer (BL2), Mesenchymal triple-negative breast cancer (M), Mesenchymal stem-like triple-negative breast cancer (MSL), Luminal androgen receptor triple-negative breast cancer (LAR), Immunomodulatory triple-negative breast cancer (IM), Metaplastic breast carcinoma, Carcinoma with medullary pattern (medullary breast cancer), Adenoid cystic carcinoma of the breast, Apocrine carcinoma of the breast, Secretory carcinoma of the breast, BRCA-associated triple-negative breast cancer, Inflammatory breast cancer, Paget disease of the nipple, Phyllodes tumour of the breast, Invasive lobular carcinoma of the breast, Invasive breast carcinoma of no special type (invasive ductal carcinoma), Tubular carcinoma of the breast, Mucinous carcinoma of the breast, Papillary carcinomas of the breast (encapsulated, solid and invasive papillary), Invasive cribriform carcinoma of the breast, Invasive micropapillary carcinoma of the breast, Neuroendocrine neoplasms of the breast, Lobular carcinoma in situ (LCIS)
Showing the organ this term concerns: Triple-negative breast cancer (TNBC).
Shares Treatment at the local hospital or at a cell-therapy centre far from home, Nodal marginal zone lymphoma, Splenic marginal zone lymphoma, Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma).
Shares Going back to work after lymphoma, and the money in the meantime, Going back to work after cancer: the rates, and the programmes that change them, Nodal marginal zone lymphoma, Splenic marginal zone lymphoma.
Shares Nodal marginal zone lymphoma, Splenic marginal zone lymphoma, Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma), Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma).
Shares Nodal marginal zone lymphoma, Splenic marginal zone lymphoma, Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma), Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma).
Shares What recovery costs in the United States, What recovery costs in the UK, and what it does not, Nodal marginal zone lymphoma, Splenic marginal zone lymphoma.
Shares Nodal marginal zone lymphoma, Splenic marginal zone lymphoma, Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma), Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma).
Shares Nodal marginal zone lymphoma, Splenic marginal zone lymphoma, Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma), Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma).
Shares Nodal marginal zone lymphoma, Splenic marginal zone lymphoma, Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma), Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma).